| Item 8.01 |
Other Events. |
On August 24, 2005, Refocus Group, Inc., or the Company, issued a press release announcing that the U.S. Food & Drug Administration granted the Company approval to begin enrollment for its Phase III clinical trial for treatment of presbyopia utilizing its Scleral Spacing Procedure. A copy of the press release announcing this approval is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Section 9 – Financial Statements and Exhibits
|
Item 9.01 Financial Statements and Exhibits. |
|
(a) |
Financial statements of businesses acquired. |
|
Not applicable. |
|
(b) |
Pro forma financial information. |
|
Not applicable. |
|
(c) |
Exhibits. |
The following exhibits are furnished in accordance with the provisions of Item 601 of Regulation S-B:
|
Exhibit Number |
Description of Exhibit |
|
|
|
|
99.1
|
Press release issued by the Company on August 24, 2005, announcing approval from the U.S. Food & Drug Administration to initiate Phase III clinical trials for the treatment of presbyopia utilizing its Scleral Spacing Procedure. |
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REFOCUS GROUP, INC. Date: August 24, 2005 By: /s/ MARK A. COX Name: Mark A. Cox Title: Vice President and Chief Financial Officer
INDEX TO EXHIBITS Exhibit Number Description of Exhibit 99.1 Press release issued by the Company on August 24, 2005, announcing approval from the U.S. Food & Drug Administration to initiate Phase III clinical trials for the treatment of presbyopia utilizing its Scleral Spacing Procedure DALLAS1 1056346v1 60915-00003
